A new genetic signature identified by Spanish researchers may provide doctors with robust and objective information about which patients with early stage lung cancer are at low or high risk of relapse following surgery, investigators report at the 3rd European Lung Cancer Conference in Geneva. Their work also opens new avenues for immunotherapy for lung cancer. Non-small cell lung cancer is a disease that is often not diagnosed until it has grown and spread throughout the body. Even those patients who are diagnosed early enough to undergo surgical removal of the tumor still have a discouraging 30% rate of relapse. Researchers hope that identifying which patients have the greatest risk of relapse will allow doctors to focus other treatment strategies, in order to improve their chance of being cured after surgery.
Researchers at the Perinatology Research Branch of the National Institutes of Health, located at the Wayne State University School of Medicine and the Detroit Medical Center, have demonstrated that a nanotechnology-based drug treatment in newborn rabbits with cerebral palsy (CP) enabled dramatic improvement of movement disorders and the inflammatory process of the brain that causes many cases of CP. The findings strongly suggest that there may be an opportunity immediately after birth for drug treatment that could minimize CP. The study is the first to show that an anti-inflammatory drug delivered with a nanodevice can dramatically improve CP symptoms in an animal model. The report, "Dendrimer-Based Postnatal Therapy for Neuroinflammation and Cerebral Palsy in a Rabbit Model, " was published in the prestigious journal Science Translational Medicine, published by the American Association for the Advancement of Science.
Balancing The Immune System: Discovery Could Aid In The Development Drugs For Organ Transplant, Autoimmune Disorders And Cancer
Loyola researchers are reporting surprising findings about a molecule that helps ramp up the immune system in some cases and suppress it in others. The finding eventually could lead to new drugs to regulate the immune system by, for example, revving it up to attack tumor cells or tamping it down to prevent the rejection of transplanted organs. The study is published online ahead of print in the Journal of Immunology. Senior author is Makio Iwashima, PhD, an associate professor in the Department of Microbiology & Immunology of Loyola University Chicago Stritch School of Medicine. Co-authors are Robert Love, MD, a professor in the Departments of Thoracic & Cardiovascular Surgery and Microbiology & Immunology and one of the world's leading lung transplant surgeons, and first author Mariko Takami, PhD, of the Department of Microbiology & Immunology.
A new brain cancer vaccine tailored to individual patients by using material from their own tumors has proven effective in a multicenter phase 2 clinical trial at extending their lives by several months or longer. The patients suffered from recurrent glioblastoma multiforme - which kills thousands of Americans every year. These results, announced at the American Association of Neurological Surgeons (AANS) meeting in Miami, compared the effectiveness of the vaccine for more than 40 patients treated at UCSF's Helen Diller Family Comprehensive Cancer Center, at the Seidman Cancer Center at University Hospitals Case Medical Center in Cleveland and at New York-Presbyterian Hospital/Columbia University Medical Center in New York City. The trial found the vaccine could extend survival for the patients by several months when compared to 80 other patients who were treated at the same hospitals and received standard therapy - 47 weeks compared to 32 weeks.
The herpes zoster vaccine, also known as the shingles vaccine, is generally safe and well tolerated according to a Vaccine Safety Datalink study of 193, 083 adults published online in the Journal of Internal Medicine. More than 1 million people develop shingles every year in the United States. Shingles is a painful contagious rash caused by the dormant chickenpox virus which can reactivate and replicate, damaging the nerve system. The elderly are especially vulnerable because immunity against the virus that causes shingles declines with age. The VSD project is a collaborative effort between the Centers for Disease Control and Prevention and integrated care organizations, including Kaiser Permanente. The VSD project monitors immunization safety and addresses the gaps in scientific knowledge about any rare and serious events that occur following immunization.